{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:55:04Z","timestamp":1768564504004,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Clin Rheumatol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Background\/Objective<\/jats:title>\n            <jats:p>The Janus kinases are cytoplasmic tyrosine kinases associated with membrane cytokine receptors that mediate signaling of multiple cytokines and growth factors, contributing to the pathogenesis of multiple autoimmune disorders. Janus kinase inhibitors (JKIs) are a new class of targeted therapies with proven efficacy in treating rheumatoid arthritis but are associated with an increased risk of infections. This study is aimed at assessing the risk of cardiovascular and venous thromboembolic events associated with JKIs in patients with rheumatoid arthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PUBMED, EMBASE, Cochrane Library, and clinicaltrials.gov were searched to identify randomized controlled trials evaluating the efficacy and safety of JKIs in patients with rheumatoid arthritis. The outcomes assessed were the risk of major adverse cardiovascular events, venous thromboembolic events, and any cardiovascular event. Sensitivity analysis disaggregated the results according to background therapy, JKI licensed doses, and studies' methodological quality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Forty-two randomized controlled trials met the inclusion criteria. No statistically significant risk differences were observed between the JKIs for any of the assessed outcomes. Compared with placebo, tofacitinib (odds ratio, 0.32; 95% confidence interval, 0.11\u20130.89) reduces the risk of venous thromboembolism. The results of the sensitivity analysis are in line with the initial findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Current evidence suggests that the risk of cardiovascular and venous thromboembolic events is similar among the JKIs. Postmarketing pharmacovigilance evidence will be of utmost importance in confirming the cardiovascular safety of these drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rhu.0000000000001804","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T22:01:37Z","timestamp":1636149697000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Risk of Cardiovascular and Venous Thromboembolic Events Associated With Janus Kinase Inhibitors in Rheumatoid Arthritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Carlos","family":"Alves","sequence":"first","affiliation":[]},{"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[]},{"given":"Diogo","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Francisco Batel","family":"Marques","sequence":"additional","affiliation":[]}],"member":"276","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"bib1-20250802","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","year":"2018","journal-title":"JAMA"},{"key":"bib2-20250802","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"bib3-20250802","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"bib11-20250802","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: first global approval","volume":"79","year":"2019","journal-title":"Drugs"},{"key":"bib12-20250802","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"bib14-20250802","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"bib15-20250802","doi-asserted-by":"crossref","first-page":"e041420","DOI":"10.1136\/bmjopen-2020-041420","article-title":"Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses","volume":"10","year":"2020","journal-title":"BMJ Open"},{"key":"bib16-20250802","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"bib17-20250802","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","year":"2019","journal-title":"BMJ"},{"key":"bib18-20250802","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","year":"2015","journal-title":"Stata J"},{"key":"bib19-20250802","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/1536867X1501500402","article-title":"Visualizing assumptions and results in network meta-analysis: the network graphs package","volume":"15","year":"2015","journal-title":"Stata J"},{"key":"bib20-20250802","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"bib21-20250802","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","year":"2013","journal-title":"Am Heart J"},{"key":"bib22-20250802","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"bib23-20250802","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"bib24-20250802","first-page":"505","article-title":"Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study","volume":"59","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"bib25-20250802","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"bib26-20250802","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and Meta-analysis","volume":"72","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"bib27-20250802","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.3390\/ijms21197390","article-title":"Clinical aspects of Janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis","volume":"21","year":"2020","journal-title":"Int J Mol Sci"},{"key":"bib28-20250802","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.thromres.2014.03.042","article-title":"Role of a Janus kinase 2\u2013dependent signaling pathway in platelet activation","volume":"133","year":"2014","journal-title":"Thromb Res"},{"key":"bib29-20250802","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12288-016-0685-8","article-title":"The impact of mean platelet volume (MPV) and JAK-2 mutation on thrombosis in chronic myeloproliferative diseases","volume":"33","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"bib30-20250802","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"bib31-20250802","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5114\/reum.2019.83236","article-title":"Cardiac and vascular complications in rheumatoid arthritis","volume":"57","year":"2019","journal-title":"Reumatologia"},{"issue":"Suppl 1","key":"bib32-20250802","first-page":"i27","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0000000000001804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T20:13:34Z","timestamp":1754165614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0000000000001804"}},"subtitle":["A Systematic Review and Network Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0000000000001804","relation":{},"ISSN":["1536-7355","1076-1608"],"issn-type":[{"value":"1536-7355","type":"electronic"},{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,3]]}}}